These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1126 related articles for article (PubMed ID: 2979857)

  • 41. [In vitro and in vivo studies of murine erythropoietic recovery after treatment with cyclophosphamide].
    Aguirre MV; Juaristi JA; Alba Alvarez M; Carmuega RJ; Brandan NC
    Sangre (Barc); 1999 Jun; 44(3):182-7. PubMed ID: 10481578
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Depletion of alloantigen-primed lymphocytes overcomes resistance to allogeneic bone marrow in mildly conditioned recipients.
    Prigozhina TB; Elkin G; Gurevitch O; Morecki S; Yakovlev E; Khitrin S; Slavin S
    Blood Cells Mol Dis; 2004; 33(3):238-47. PubMed ID: 15528138
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The effect of NGF on hematopoiesis of granulocyte-macrophage in normal and radiation, chemistry injury mice].
    Huang XQ; Zhu BD; Jiang-Yang-ze-ren
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):757-62. PubMed ID: 19024307
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A correlation between conditioning and engraftment in recipients of MHC-mismatched T cell-depleted murine bone marrow transplants.
    Soderling CC; Song CW; Blazar BR; Vallera DA
    J Immunol; 1985 Aug; 135(2):941-6. PubMed ID: 3891856
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The origin of cytotoxic T lymphocyte precursors (CTL-P): MHC-restricted and alloreactive CTL-P in the spleen during regeneration after a sublethal dose of cyclophosphamide (Cy).
    Sihvola M; Hurme M
    J Immunol; 1983 Mar; 130(3):1077-83. PubMed ID: 6600471
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevention of acute graft-vs-host disease by a single low-dose cyclophosphamide injection following allogeneic bone marrow transplantation.
    Prigozhina TB; Elkin G; Khitrin S; Slavin S
    Exp Hematol; 2008 Dec; 36(12):1750-9. PubMed ID: 18809241
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lymphocyte aging in bone marrow chimeras.
    Armstrong MJ; Janick-Buckner D; Harvey N; Briggs CJ; Warner CM
    Growth Dev Aging; 1993; 57(4):251-60. PubMed ID: 8300278
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combined effect of levan and cytotoxic agents on the growth of experimental tumours in mice.
    Leibovici J; Stark Y; Wolman M
    Br J Exp Pathol; 1983 Jun; 64(3):239-44. PubMed ID: 6882675
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Histological changes in spleen and lymph nodes of mice administered cyclophosphamide and levan.
    Siegal A; Kopel S; Leibovici J
    Cell Tissue Res; 1986; 245(1):183-8. PubMed ID: 3488127
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The effects of ICA on the cell-immunosuppressive and bone-marrow-suppressive mice after chemotherapy].
    Zhao LM; Ji X; Shan BE; Han LN; Pan XM; Peng H; Ma M
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2010 Oct; 26(10):976-9. PubMed ID: 20937233
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Quantitative and qualitative effects of cyclophosphamide administration on circulating polymorphonuclear leucocytes.
    Hunninghake GW; Fauci AS
    Immunology; 1976 Jul; 31(1):139-44. PubMed ID: 1027718
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ultrastructural changes of stromal cells of bone marrow and liver after cyclophosphamide treatment in mice.
    Anton E
    Tissue Cell; 1997 Feb; 29(1):1-9. PubMed ID: 9061976
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of administration schedule on the levan-cyclophosphamide combined treatment of Lewis lung carcinoma.
    Stark Y; Leibovici J; Wolman M
    Int J Immunopharmacol; 1983; 5(4):289-97. PubMed ID: 6629589
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antagonistic effect of heparin and a water-soluble glucocorticoid on the peripheral lymphocyte count in mice.
    Jókay I; Karczag E
    Haematologia (Budap); 1977; 11(1-2):103-10. PubMed ID: 615083
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Study on zinc resistance to the immunosuppression caused by cyclophosphamidum in the mouse].
    Zhang XH; Wang L; Dong ZZ
    Sheng Li Xue Bao; 1992 Oct; 44(5):528-32. PubMed ID: 1293769
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Changes in the number and qualitative state of lymphocytes in a joint chronic lesion from strontium-90 and lindane in rats].
    Ivanov VV
    Gig Sanit; 1988 Feb; (2):37-9. PubMed ID: 2453396
    [No Abstract]   [Full Text] [Related]  

  • 57. The inhibitory effects of high molecular levan on transport across the vascular wall stimulated by histamine.
    Walters MN; Wolman M; Robertson TA; Papadimitriou JM
    J Pathol; 1978 Apr; 124(4):195-203. PubMed ID: 722383
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of deuteration on hematopoiesis in the mouse.
    Adams WH; Adams DG
    J Pharmacol Exp Ther; 1988 Feb; 244(2):633-9. PubMed ID: 2831349
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cyclophosphamide induced generation of giant hypersegmented granulocytes in rat bone marrow: cell cycle distribution and silver nucleolar staining.
    Kotelnikov VM; Pogorelov VM; Berger J; Kozinets GI
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(5):737-45. PubMed ID: 2465255
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inhibitory and stimulatory effects of levan on growth of B16 melanoma--possible mechanisms.
    Yavetz H; Davidai G; Leibovici J; Wolman M
    Cell Mol Biol; 1985; 31(5):343-7. PubMed ID: 4084939
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 57.